Melasma (Chloasma)
Last Updated: 2026-11-19
Author(s): Navarini A.
ICD11: -
Cite
Permalink
Publication History
Version 1
03 April 2021
Version 2
19 November 2026
Melasma, pregnancy spots, chloasma
Acquired hyperpigmentation of facial skin, clearly associated clinically with sun exposure. Pigmentation may lighten with reduced light exposure but can persist or relapse throughout the year.
Very common, particularly in women with darker skin of childbearing age; much less common in men. The main risk factors are pregnancy and contraceptive use.
-
Clinical patterns: centrofacial, malar and mandibular.
-
Predominantly epidermal, dermal or mixed pigmentation; depth assessments have limited ability to predict response.
-
Historic labels such as hepaticum / cachecticorum are not accepted aetiological subtypes; exclude alternative causes of facial pigmentation.
In melasma, melanogenesis is increased through complex interactions between the epidermis and dermis. Visible light contributes to pigmentation alongside UV radiation. Consistent photoprotection is therefore essential for treatment and relapse prevention: recommendations include adjusted sun exposure, protective clothing and a broad-spectrum sunscreen containing iron oxide pigments for protection against visible light.
Clearly hyperpigmented macules distributed approximately symmetrically on the face, ranging from small spots to large, irregularly shaped patches, never infiltrated.
Pregnancy may also cause physiological areolar, genital and linea nigra pigmentation; these are distinct from facial melasma.
Typical clinical presentation, dermoscopic pattern and relevant history.
Forehead, both temples, cheeks, upper lip and other facial regions.
Melanin accumulation extends from the stratum basale to beneath the stratum corneum; pigment incontinence also occurs, with melanin-containing macrophages in the upper dermis.
Chronic and relapsing; recurrence is common with light exposure but is not invariably seasonal.
Core treatment
-
Topical depigmentation and consistent photoprotection form the basis of treatment.
-
Options include hydroquinone, azelaic acid, or a triple combination of hydroquinone, tretinoin, and a corticosteroid.
-
Select treatment according to skin sensitivity, tolerability, and pregnancy status.
Triple-combination products
-
Products are not interchangeable internationally.
-
The Swiss Pigmanorm formulation contains hydroquinone 5%, tretinoin 0.03%, and dexamethasone 0.03%; other countries use different corticosteroids or strengths.
-
Prescribe the exact ingredients and a time-limited course rather than a brand name alone.
Safety
-
Hydroquinone can cause irritation and, rarely, exogenous ochronosis.
-
Hydroquinone and triple-combination treatment are not recommended during pregnancy or breastfeeding.
Procedural and specialist options
-
Chemical peels and pigment lasers administered by appropriately trained practitioners can supplement topical treatment.
-
Avoid medium-depth peels.
-
Oral tranexamic acid is an off-label specialist option for selected refractory disease.
-
Screen for thromboembolic risk and avoid oral tranexamic acid in patients with thrombosis risk or combined hormonal contraceptive use.
Photoprotection
- Strict photoprotection remains necessary.
-
Sarkar R, et al. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2026;40:680–692. doi:10.1111/jdv.70066.
-
Arellano I, Cestari T, Ocampo-Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. J Eur Acad Dermatol Venereol. 2012;26:611.
-
Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893.
-
Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015;72:189.
-
Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014;30:35.
-
Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697.
-
Del Rosario E, Florez-Pollack S, Zapata L Jr, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78:363.
-
Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010;62:962.
-
Grimes PE, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2019;5:30.
-
Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453.
-
Janney MS, Subramaniyan R, Dabas R, et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019;12:63.
-
Karrabi M, David J, Sahebkar M. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study. Skin Res Technol. 2021;27:24.
-
Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46:111.
-
Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63:1030.
-
Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous Pathology of Melasma and Its Clinical Implications. Int J Mol Sci. 2016;17.
-
Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol. 2007;21:738.
-
Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75:385.
-
Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;173:209.
-
Minni K, Poojary S. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. J Eur Acad Dermatol Venereol. 2020;34:2636.
-
Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatol Res Pract. 2011;2011:379173.
-
Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781.
-
Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017;7:305.
-
Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010; :CD003583.
-
Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. J Cutan Aesthet Surg. 2012;5:247.
-
Sarma N, Chakraborty S, Poojary SA, et al. Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma. Indian Dermatol Online J. 2017;8:406.
-
Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67.
-
Trivedi MK, Yang FC, Cho BK. A review of laser and light therapy in melasma. Int J Womens Dermatol. 2017;3:11.
-
Zhang L, Tan WQ, Fang QQ, et al. Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:1683414.
-
Ocampo-Candiani J, Alas-Carbajal R, Bonifaz-Araujo JF, et al. Latin American consensus on the treatment of melasma. Int J Dermatol. 2025;64:499–512. doi:10.1111/ijd.17522.
-
Swissmedic. Pigmanorm: approved professional information; Swiss formulation and treatment duration. Available online.
This website uses cookies!
We use cookies to tailor our content to your needs and continuously improve our website. You can decide which cookies you want to allow. Detailed information about the cookies we use can be found in our Privacy Policy and Cookie Settings. You can withdraw your consent at any time.